EDX Medical has entered into a distribution agreement with Caris Life Sciences, a US company specialising in AI-driven precision medicine. This collaboration will see both companies working together to distribute Caris’ advanced molecular profiling services across the UK and Nordic countries, with the partnership set to last for at least three years on a mutually exclusive basis.
EDX Medical is known for developing cutting-edge digital diagnostic products that aid in personalised treatments for diseases such as cancer, heart disease, and infectious diseases. As part of the agreement, EDX Medical will exclusively offer Caris’ solid tumour and liquid biopsy molecular profiling services, as well as AI solutions, across the UK, Sweden, Denmark, Norway, and Finland, with future plans to expand these services to other regions.
Professor Sir Chris Evans, founder of EDX Medical, highlighted the significance of this deal, stating that it marks a crucial step forward in providing clients with top-tier diagnostic tools that can transform the detection and treatment of illnesses. He emphasised the importance of whole exome and transcriptome analysis, which offers a comprehensive examination of genetic material for cancer patients, thus ensuring the most accurate treatment decisions.
Mike Hudson, CEO of EDX Medical, expressed that both EDX and Caris are driven by a shared mission of offering doctors the most advanced biological insights from patient samples. Caris’ approach to molecular profiling, which includes in-house artificial intelligence, helps physicians to make more precise, personalised cancer treatment decisions. The platform evaluates DNA, RNA, and proteins, delivering a detailed molecular profile for each patient to identify the most appropriate treatment options. Their system, which includes Whole Exome and Whole Transcriptome Sequencing, covers more than 23,000 genes and is one of the most comprehensive cancer analysis platforms globally.
David Spetzler, President of Caris Life Sciences, expressed his enthusiasm for the collaboration, stating that it aligns with Caris’ mission of supporting clinicians in making personalised treatment choices, ultimately improving patient outcomes.
This strategic partnership between EDX Medical and Caris Life Sciences promises to provide enhanced access to world-class molecular profiling services, revolutionising personalised medicine in the UK and Nordic countries.
EDX Medical Group Plc (AQSE:EDX) is a global specialist in digital clinical diagnostics; developing and supporting high-performance products and services to provide cost-effective prediction of disease risk, inform clinical decision-making, enable personalised healthcare and accelerate the development of new medicines for cancer, neurology, heart disease and infectious diseases.
